parkinson, Parkinson's research notebook

Six readers

reader	found	score
genetics Open Targets	no genetic evidence; overall 0.00 from other evidence	0.00
cell type Human Protein Atlas	cell type enhanced, including astrocytes; strongest in endometrial glandular cells	0.75
chemistry Open Targets	hard to drug	0.00
trials ClinicalTrials.gov	no Parkinson's trials on record: an open field	1.00
literature PubMed	no papers tie it to Parkinson's yet	1.00
pathways Reactome	in no curated pathway	0.00

No case: the score is under the bar. Receipt 13359

GRAMD2B in astrocytes, braak+0.63 (p 0.068) → +0.17 (p 0.656)receipt 13367
GRAMD2B in dopamine neurons, braak+0.02 (p 0.964) → -0.18 (p 0.648)receipt 13368

receipt 13368: GRAMD2B in dopamine neurons, braak

power: full sample +0.03 (p 0.901, n 18), 95% CI -0.44 to +0.49. the interval is wide: not enough donors to tell.
confounder: adjusted for sex: +0.06 (p 0.820, n 18). does not hold up.
composition: dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: +0.13 (p 0.615, n 18). could be the mix.
skeptic: leave-one-out range -0.05 to +0.18, sign flips 6; without severely affected donors +0.03 (p 0.901, n 18). fragile.
cell type: no other cell group does better.
axis: no measure beats "tracks Braak Lewy-body stage" for GRAMD2B in dopamine neurons.

case closed: nothing better to follow up.

receipt 13367: GRAMD2B in astrocytes, braak

power: full sample +0.40 (p 0.103, n 18), 95% CI -0.09 to +0.73. the interval is wide: not enough donors to tell.
confounder: adjusted for sex: +0.38 (p 0.120, n 18). does not hold up.
composition: astrocytes share of nuclei vs axis -0.21 (p 0.413); controlling for it: +0.38 (p 0.120, n 18). could be the mix.
skeptic: leave-one-out range +0.32 to +0.58, sign flips 0; without severely affected donors +0.40 (p 0.103, n 18). fragile.
cell type: no other cell group does better.
axis: no measure beats "tracks Braak Lewy-body stage" for GRAMD2B in astrocytes.

case closed: nothing better to follow up.

loading the receipts